Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220902 · ClinicalTrials.gov registry record · Phase 3
Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure
A Phase 3 study, sponsored by Nebraska Methodist Health System.
- Not yet
- Registry status
- Phase 3
- Development phase
- 1,240
- Enrollment target
NCT07220902 is a Phase 3 study that has not yet begun recruiting, run by Nebraska Methodist Health System. The registered enrollment target is 1,240 participants.
The verdict
NCT07220902, a Phase 3 study, has not yet begun recruiting, sponsored by Nebraska Methodist Health System.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,240 participants
- Enrollment target
Study Summary
The goal of this study is to compare levetiracetam to magnesium sulfate for the prevention of eclamptic seizures in pregnant persons with severe preeclampsia that are 32 or more weeks pregnant. This is an equivalence study so our primary goal is to see no difference in the incidence of seizure in the two groups. Since side effects can be a significant problem with magnesium sulfate and these patients are at significant risk of life threatening complications, we also plan to evaluate several secondary outcomes in the mothers and the babies, including: severe allergic reaction, magnesium toxicity, ICU admission, hospital readmission, transfusion for any reason, pulmonary edema, cardiomyopathy, Posterior Reversible Encephalopathy Syndrome, eclamptic seizure, loss of vision, stroke, renal injury requiring dialysis, cardiac arrest, maternal death, unexpected stillbirth or neonatal death, NICU admission, Apgars and length of neonatal respiratory support.
Interventions
- DRUG Levetiracetam
- DRUG magnesium sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,240 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2034-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07220902
The ClinicalTrials.gov registry entry for NCT07220902 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 1,240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nebraska Methodist Health System, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levetiracetam is the first listed.
NCT07220902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07220902 about?
NCT07220902 is a clinical study titled "Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure". The goal of this study is to compare levetiracetam to magnesium sulfate for the prevention of eclamptic seizures in pregnant persons with severe preeclampsia that are 32 or more weeks pregnant. This is an equivalence study so our primary goal is to see no difference in the incidence of seizure in th...
What is the current status of trial NCT07220902?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 1,240 participants. The study started on 2026-01-01. Estimated completion is 2034-07.
What interventions are being tested in trial NCT07220902?
The interventions under investigation include: Levetiracetam (DRUG), magnesium sulfate (DRUG).
Who is sponsoring clinical trial NCT07220902?
This trial is sponsored by Nebraska Methodist Health System, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.